Technical Analysis for FDMT - 4D Molecular Therapeutics, Inc.

Grade Last Price % Change Price Change
F 8.10 1.06% 0.09
FDMT closed up 1.06 percent on Friday, November 1, 2024, on 58 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Nov 7
*** please verify all earnings dates ***
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 1.06%
NR7 Range Contraction 1.06%
Stochastic Reached Oversold Weakness 1.06%
Oversold Stochastic Weakness 1.06%
180 Bearish Setup Bearish Swing Setup -1.28%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 19 hours ago
Possible NR7 about 19 hours ago
Possible Inside Day about 19 hours ago
60 Minute Opening Range Breakout about 23 hours ago
Up 3% about 23 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

4D Molecular Therapeutics, Inc. Description

4DMT is a clinical-stage gene therapy company pioneering the development of product candidates using targeted and evolved AAV vectors. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. The company is initially focused in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The 4DMT targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. 4DMT is currently conducting three clinical trials: 4D-125 is in a Phase 1/2 clinical trial for XLRP, 4D-110 is in a Phase 1 clinical trial for choroideremia and 4D-310 is in a Phase 1/2 clinical trial for Fabry disease.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Biology Emerging Technologies Antibodies Molecular Biology Gene Therapy Medical Genetics Gene Delivery Fabry Disease Gene Therapy Products Choroideremia Gene Therapy Of The Human Retina

Is FDMT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 36.25
52 Week Low 7.9
Average Volume 821,669
200-Day Moving Average 20.90
50-Day Moving Average 11.72
20-Day Moving Average 8.60
10-Day Moving Average 8.29
Average True Range 0.53
RSI (14) 30.56
ADX 46.45
+DI 9.37
-DI 26.73
Chandelier Exit (Long, 3 ATRs) 8.98
Chandelier Exit (Short, 3 ATRs) 9.48
Upper Bollinger Bands 9.40
Lower Bollinger Band 7.80
Percent B (%b) 0.19
BandWidth 18.60
MACD Line -0.98
MACD Signal Line -1.15
MACD Histogram 0.1706
Fundamentals Value
Market Cap 399.4 Million
Num Shares 49.3 Million
EPS -2.65
Price-to-Earnings (P/E) Ratio -3.05
Price-to-Sales 62.23
Price-to-Book 4.02
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.47
Resistance 3 (R3) 8.48 8.37 8.41
Resistance 2 (R2) 8.37 8.28 8.37 8.39
Resistance 1 (R1) 8.23 8.22 8.30 8.22 8.37
Pivot Point 8.12 8.12 8.16 8.12 8.12
Support 1 (S1) 7.98 8.03 8.05 7.97 7.82
Support 2 (S2) 7.87 7.97 7.87 7.80
Support 3 (S3) 7.73 7.87 7.78
Support 4 (S4) 7.72